Abstract | PURPOSE: PATIENTS AND METHODS: The Metformin and AcaRbose Clinical Trial was a randomized, open-label trial in newly diagnosed T2DM patients. Participants received 48 weeks of monotherapy with acarbose (100 mg three times a day) or metformin (1500 mg once a day). As the hypoglycemic effect of acarbose and metformin has been evaluated in previous reports. This analysis studied the effect of the two antidiabetic drugs on reducing urinary albumin. The percent change in the urinary albumin/ creatinine ratio (uACR) from baseline to week 48 was analyzed, and ANCOVA was employed to establish whether the effect in decreasing uACR was mediated by metabolic improvement. RESULTS: CONCLUSION:
|
Authors | Lulu Song, Xiaomu Kong, Zhaojun Yang, Jinping Zhang, Wenying Yang, Bo Zhang, Xiaoping Chen, Xin Wang |
Journal | Diabetes, metabolic syndrome and obesity : targets and therapy
(Diabetes Metab Syndr Obes)
Vol. 14
Pg. 4451-4458
( 2021)
ISSN: 1178-7007 [Print] New Zealand |
PMID | 34764663
(Publication Type: Case Reports, Clinical Trial)
|
Copyright | © 2021 Song et al. |